|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
18 April 2017 |
|
Main ID: |
ChiCTR-OOC-14005312 |
|
Date of registration:
|
2014-09-24 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
An International Multicenter Prospective Observational Study to Evaluate the Epidemiology, Humanistic and Economic Outcomes of Treatment for Chronic Hepatitis C Virus (HCV)
|
|
Scientific title:
|
An International Multicenter Prospective Observational Study to Evaluate the Epidemiology, Humanisti |
|
Date of first enrolment:
|
2014-11-01 |
|
Target sample size:
|
All people:5000; |
|
Recruitment status: |
Completed |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=9624 |
|
Study type:
|
Observational study |
|
Study design:
|
Cross-sectional
|
|
Phase:
|
Other
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Chunyan Yuan
|
|
Address:
|
17/F, Chong Hing Finance Center, No.288 West Nanjing Road, Shanghai, China
200003
|
|
Telephone:
|
+86 21-62631361 |
|
Email:
|
chunyan.yuan@abbvie.com |
|
Affiliation:
|
Abbvie Pharmaceutical Trading (Shanghai) Co.,Ltd. |
|
|
Name:
|
Chunyan Yuan
|
|
Address:
|
17/F, Chong Hing Finance Center, No.288 West Nanjing Road, Shanghai, China
200003
|
|
Telephone:
|
+86 21-62631361 |
|
Email:
|
chunyan.yuan@abbvie.com |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Diagnosed of having a chronic HCV infection;
2. Male or female and 18 years of age or older;
3. Speaks the language of the provided patient questionnaires;
4. Signed a patient authorization form to use and disclose personal health information (or informed consent, where applicable).
Exclusion criteria: 1. Diagnosed of having an acute HCV infection;
2. Currently on treatment for HCV;
3. Participates in a concurrent interventional clinical trial (phase 1, 2 or 3 or a Compassionate Use or Early Access Program).
Age minimum:
18
Age maximum:
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Hepatitis C Virus
|
|
Intervention(s)
|
|
All people:N/A;
|
|
Primary Outcome(s)
|
|
Description of the general epidemiology of patient;Proportion of patients planned for IFN containing ;Changes in HRQoL (EQ-5D-5L and HCV-PRO) over the t;Treatment completion status:a) Includes determinin;Percentages of presenteeism, absenteeism, total wo;Degree of resource utilization associated with HCV;
|
|
Source(s) of Monetary Support
|
|
Abbvie Pharmaceutical Trading (Shanghai) Co., Ltd.
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|